Table 3

FEV1 at study entry, follow-up and annual decline by number of respiratory symptoms among women, men and all participants

FEV1pp pre-BD at study entryFEV1pp pre-BD at follow-upAnnual decline in FEV1pp
Women
 None or 1 symptomsn=20692.3 (11.8)92.8 (15.1)0.040 (0.580)
 2 symptomsn=15789.5 (12.7)90.2 (15.2)0.048 (0.611)
 3 symptomsn=12788.8 (12.8)87.9 (16.0)−0.035 (0.666)
 4 symptomsn=5585.5 (13.4)87.0 (15.8)0.084 (0.550)
 P value0.0010.0110.553
Men
 None or 1 symptomsn=21689.2 (14.1)85.0 (14.8)−0.207 (0.583)
 2 symptomsn=11084.6 (14.4)83.2 (15.3)−0.044 (0.670)
 3 symptomsn=8783.1 (16.1)78.0 (19.0)−0.287 (0.606)
 4 symptomsn=1983.3 (15.0)79.0 (19.3)−0.303 (0.772)
 P value0.0020.0050.031
Total
 None or 1 symptomsn=42290.7 (13.1)88.8 (15.4)−0.086 (0.594)
 2 symptomsn=26787.5 (13.6)87.3 (15.6)0.010 (0.636)
 3 symptomsn=21486.5 (14.5)83.8 (17.9)−0.137 (0.652)
 4 symptomsn=7484.9 (13.7)84.9 (17.0)−0.016 (0.632)
 P value<0.0010.0020.052
  • Results presented as mean (SD) and p values from ANOVA in bold figures indicate p<0.05.

  • Included respiratory symptoms: recurrent wheeze, dyspnoea, longstanding cough, productive cough.

  • ANOVA, analysis of variance; FEV1, forced expiratory volume in 1 s; Pre-BD, pre-bronchodilatation.